Randomized comparative study of HCC with MPVTT treated by portal vein stent and TACE combined with or without

Linlin Wu,Jianjun Luo,Zhiping Yan,Zhuting Fang,Wen Zhang,Xuebin Zhang,Jianhua Wang,Xiaolin Wang
DOI: https://doi.org/10.3969/j.issn.1672-8467.2013.03.020
2013-01-01
Abstract:Objective: To randomized block design and compare the efficacy of hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT) treated by portal vein stent and transcatneter arterial chemoembolization (TACE) combined with or without endovascular implantation of Iodine-125 (125I) seeds strand. Methods: Sixty patients with HCC complicated by MPVTT who received portal vein stent and TACE combined with (group A, n=30) or without (group B, n=30) endovascular implantation of 125I seeds strand in our hospital during Feb. 2009 and Apr. 2011 were analyzed retrospectively. Overall survival, stent patency and procedure-related adverse event were compared between the two groups. Results: Technical success rate was 100% for placement of 125I seeds strand and stent in the obstructed main portal vein. No serious procedure-related adverse events occurred. Median survival time of group A and B were 335 days and 142 days, respectively (P=0.002, HR=2.683); Median stent patency period of group A and B were 340 days and 190 days, respectively (P=0.038, HR=2.252). Conclusions: Portal vein stent and TACE combined with endovascular implantation of 125I seeds strand could improve the survival time, stent patency period of patients with HCC complicated by MPVTT and improve their quality of life effectively. It is a new approach to treat HCC with MPVTT.
What problem does this paper attempt to address?